• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Terns Pharmaceuticals Inc (NQ: TERN )

    8.670 -0.300 (-3.34%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Jul 24, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 745,378
    Open 8.850
    Bid (Size) 8.730 (50)
    Ask (Size) 9.490 (50)
    Prev. Close 8.970
    Today's Range 8.420 - 9.030
    52wk Range 3.260 - 10.03
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Can These 2 Biotechs Beat Eli Lilly and Novo Nordisk in Weight-Loss Drugs?
    At least one of the pair has a credible shot at finding a home in the market. 
    Via The Motley Fool
    EXCLUSIVE: Weight-Loss Duopoly Breaks As Eli Lilly, Novo Plummet; 'Market Won't Be Dominated By Just 2 Players'
    Eli Lilly and Novo Nordisk face selloff as new weight-loss drugs threaten dominance. Shares of both companies drop significantly, highlighting need for diversification in this industry. 
    Via Benzinga

    Performance

    YTD
    +33.80%
    +33.80%
    1 Month
    +15.29%
    +15.29%
    3 Month
    +82.53%
    +82.53%
    6 Month
    +60.56%
    +60.56%
    1 Year
    +26.02%
    +26.02%

    More News

    Read More
    Why ConAgra Brands Shares Are Trading Lower? Here Are Other Stocks Moving In Thursday's Mid-Day Session
    Via Benzinga
    TERN Stock Earnings: Terns Pharma Meets EPS for Q4 2023
    Via InvestorPlace
    Methode Electronics Posts Strong Sales, Joins QuantumScape, Ribbon Communications And Other Big Stocks Moving Higher On Thursday
    Via Benzinga
    Terns Pharmaceuticals Highlights New Preclinical Data Supporting TERN-501 in Combination with a GLP-1R Agonist for Obesity at the ADA’s 84th Annual Scientific Sessions and Upcoming Conference Participation
    From Terns Pharmaceuticals, Inc.
    Via GlobeNewswire
    Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)
    From Terns Pharmaceuticals, Inc.
    Via GlobeNewswire
    Terns Pharmaceuticals to Participate in Upcoming June Investor Conferences
    From Terns Pharmaceuticals, Inc.
    Via GlobeNewswire
    Terns Pharmaceuticals to Participate in UBS Obesity Therapeutics Day
    From Terns Pharmaceuticals, Inc.
    Via GlobeNewswire
    TERN Stock Earnings: Terns Pharma Beats EPS for Q1 2024
    Via InvestorPlace
    Terns Pharmaceuticals Reports First Quarter 2024 Financial Results and Corporate Updates
    From Terns Pharmaceuticals, Inc.
    Via GlobeNewswire
    Terns Pharmaceuticals Announces Leadership Changes
    From Terns Pharmaceuticals, Inc.
    Via GlobeNewswire
    Terns Pharmaceuticals to Participate in The Citizens JMP Life Sciences Conference 2024
    From Terns Pharmaceuticals, Inc.
    Via GlobeNewswire
    Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)
    From Terns Pharmaceuticals, Inc.
    Via GlobeNewswire
    Terns Pharmaceuticals Announces Data from Ongoing Phase 1 Pharmacokinetic Study of Allosteric BCR-ABL Inhibitor TERN-701 in Adult Healthy Volunteers and Highlights Potential for Competitive Differentiation
    From Terns Pharmaceuticals, Inc.
    Via GlobeNewswire
    Terns Pharmaceuticals Appoints Melita Sun Jung as Chief Business Officer
    From Terns Pharmaceuticals, Inc.
    Via GlobeNewswire
    Wall Street’s Favorite Biotech Stocks? 3 Names That Could Make You Filthy Rich
    Via InvestorPlace
    12 Health Care Stocks Moving In Thursday's After-Market Session
    Via Benzinga
    Madrigal Pharmaceuticals Wins Approval for the First Drug Targeting the Multibillion-Dollar NASH Market. Is the Stock a Screaming Buy?
    Via The Motley Fool
    Terns Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates
    From Terns Pharmaceuticals, Inc.
    Via GlobeNewswire
    Terns Pharmaceuticals Announces Orphan Drug Designation Granted to TERN-701 for the Treatment of Chronic Myeloid Leukemia
    From Terns Pharmaceuticals, Inc.
    Via GlobeNewswire
    Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)
    From Terns Pharmaceuticals, Inc.
    Via GlobeNewswire
    Terns Pharmaceuticals to Participate in Upcoming March Investor Conferences
    From Terns Pharmaceuticals, Inc.
    Via GlobeNewswire
    Terns Pharmaceuticals Reports Inducement Grants to New Chief Executive Officer Under Nasdaq Listing Rule 5635(C)(4)
    From Terns Pharmaceuticals, Inc.
    Via GlobeNewswire
    Why Take-Two Interactive Software Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Friday's Mid-Day Session
    Via Benzinga
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.